- $4.32bn
- $4.10bn
- $1.39bn
LivaNova rises on Q2 results beat
LivaNova PLC reports results for the quarter ended in June - Earnings Summary
Brief: LivaNova Q2 Adjusted EPS USD 0.78 Vs. IBES Estimate USD 0.54
LivaNova PLC expected to post earnings of 54 cents a share - Earnings Preview
Competition and Mkts - Medivet/multiple independent veterinary businesses
LivaNova PLC reports results for the quarter ended in March - Earnings Summary
Brief: LivaNova Reports Q1 adjusted EPS of USD 0.43
LivaNova PLC expected to post earnings of 39 cents a share - Earnings Preview
LivaNova rises on upbeat prelim Q1 revenue; CEO resigns
Brief: LivaNova Announces Damien Mcdonald's Resignation As CEO
On March 23, 2023, Livanova Randomized 500Th Unipolar Patient Into Trial
Brief: Livanova Receives U.S. FDA 510(K) Clearance For Essenz Heart-Lung Machine
LivaNova PLC reports results for the quarter ended in December - Earnings Summary
Brief: LivaNova Expects FY2023 Revenue Growth Of 3-5%
Brief: LivaNova Reports Fourth Quarter Results
LivaNova PLC expected to post earnings of 73cents a share - Earnings Preview
Brief: LivaNova Initiates Limited Commercial Release In Europe Of Essenz Perfusion System
FDA classifies recall of LivaNova's blood-pumping system controller as most serious
Brief: LivaNova Announces Receipt Of Close-Out Of Warning Letter From U.S. Food And Drug Administration